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Abstract
Background: Blood glucose control in the intensive care unit (ICU) has the potential to save lives. However,
maintaining blood glucose concentrations within a chosen target range is difficult in clinical practice and holds risk
of potentially harmful hypoglycemia. Clinically validated computer algorithms to guide insulin dosing by nurses
have been advocated for better and safer blood glucose control.
Methods: We conducted an international, multicenter, randomized controlled trial involving 1550 adult, medical and
surgical critically ill patients, requiring blood glucose control. Patients were randomly assigned to algorithm-guided
blood glucose control (LOGIC-C, n = 777) or blood glucose control by trained nurses (Nurse-C, n = 773) during ICU stay,
according to the local target range (80–110 mg/dL or 90–145 mg/dL). The primary outcome measure was the quality
of blood glucose control, assessed by the glycemic penalty index (GPI), a measure that penalizes hypoglycemic and
hyperglycemic deviations from the chosen target range. Incidence of severe hypoglycemia (<40 mg/dL) was the main
safety outcome measure. New infections in ICU, duration of hospital stay, landmark 90-day mortality and quality of life
were clinical safety outcome measures.
Results: The median GPI was lower in the LOGIC-C (10.8 IQR 6.2–16.1) than in the Nurse-C group (17.1 IQR 10.6–26.2)
(P < 0.001). Mean blood glucose was 111 mg/dL (SD 15) in LOCIC-C versus 119 mg/dL (SD 21) in Nurse-C, whereas the
median time-in-target range was 67.0% (IQR 52.1–80.1) in LOGIC-C versus 47.1% (IQR 28.1–65.0) in the Nurse-C group
(both P < 0.001). The fraction of patients with severe hypoglycemia did not differ between LOGIC-C (0.9%) and Nurse-C
(1.2%) (P = 0.6). The clinical safety outcomes did not differ between groups. The sampling interval was 2.3 h (SD 0.5) in
the LOGIC-C group versus 3.0 h (SD 0.8) in the Nurse-C group (P < 0.001).
Conclusions: In a randomized controlled trial of a mixed critically ill patient population, the use of the LOGIC-Insulin
blood glucose control algorithm, compared with blood glucose control by expert nurses, improved the quality of
blood glucose control without increasing hypoglycemia.
Trial registration: ClinicalTrials.gov, NCT02056353. Registered on 4 February 2014.
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Background
Elevated blood glucose levels are very common in critic-
ally ill patients, independent of pre-existing diabetes
mellitus. This hyperglycemia has been associated with
an increased risk of morbidity and mortality [1]. Tight
blood glucose control (BGC), targeting blood glucose
levels below 110 mg/dL, improved the outcome of
critically ill patients only in well-controlled single-center
trials and in implementation studies [2–6]. In large
multicenter trials, however, this beneficial effect was not
reproduced and in the NICE-SUGAR trial mortality even
increased in the intensive BGC group [7–9]. While
excessive hyperglycemia above 180 mg/dL is no longer
accepted, the target range for BGC is still controversial
and variable [10]. The American Diabetes Association
recommends targeting blood glucose levels below
180 mg/dL, while in Europe most centers use stricter
target ranges (below 145 mg/dL), despite a lack of
evidence [11, 12].
Excess mortality in patients undergoing BGC has been
attributed to the increased incidence of hypoglycemia
and unnecessary blood glucose variability [13, 14].
Inaccurate blood glucose measurements and the use of
insulin dosing protocols that have not been clinically val-
idated play an important role herein [15]. BGC requires
not only frequent measurements of blood glucose, but
also difficult calculations of the insulin doses, depending
on the protocol. Moreover, BGC has to be done in
severely ill patients, who may undergo rapid changes in
their insulin sensitivity due to the underlying illness and
medication such as parenteral nutrition and steroids. To
obtain better (less hyperglycemia) and safer (less
hypoglycemia) BGC it has been advocated to use com-
puterized protocols for insulin dosing and timing of
blood glucose measurements [16, 17]. However, the
current evidence for these computer algorithms consists
primarily of implementation studies or small randomized
controlled studies [18–22]. Therefore, their use has not yet
been widely adopted in general clinical practice although a
growing number of ICUs are starting to use validated
computer algorithms with a beneficial effect on blood
glucose control, such as EndoTool and STAR [23, 24].
The LOGIC-Insulin algorithm, developed and based
on the Leuven guideline and practice, had already been
clinically validated in a single-center randomized trial,
showing improved and safer BGC (below 110 mg/dL),
compared to that performed by nurses who were highly
experienced in BGC [25]. However, performance of the
algorithm in a setting of different blood glucose target
ranges, in a wide-ranging patient population, by nurses
with less experience in BGC has not yet been evaluated
in a pragmatic, multicenter setting. Therefore, we hy-
pothesized that the LOGIC-Insulin algorithm improves
the quality of BGC, in comparison with nurse-directed
BGC, using two different glucose target ranges (80–
110 mg/dL or 90–145 mg/dL) in a heterogeneous
population of critically ill adults and in the setting of a
nursing staff with variable levels of expertise.
Methods
Study design
We conducted a pragmatic, parallel-group, observer-
blinded, randomized controlled trial, involving medical
and surgical patients admitted to the ICUs of three hos-
pitals: two tertiary referral academic centers (University
Hospitals of the KU Leuven, Leuven, Belgium and
Academic Medical Center at the University of
Amsterdam, Amsterdam, The Netherlands) and one
non-academic, teaching hospital (Jessa Hospital, Hasselt,
Belgium). All ICUs involved have a closed organization,
staffed by full-time intensivists, and represent, respect-
ively, 98, 50, and 36 ICU beds.
The study protocol and informed consent documents
were approved by the Belgian Federal Agency for
Medicines and Health Products (80 M0563) and the
institutional review boards of each participating center.
The trial was registered on ClinicalTrials.gov
(NCT02056353) on 4 February 2014. No design changes
occurred during the trial. Whenever possible, informed
consent was asked for from the decision-competent pa-
tient before study inclusion. In the case of emergency
ICU admissions, deferred proxy consent from the legal
representative was obtained. The data and safety moni-
toring board (DSMB) reviewed the data twice according
to the charter and advised continuation according to the
initial protocol.
Participants
Patients were recruited from 24 February 2014 to 17
December 2014. All patients admitted to the ICU with an
expected stay of at least 2 days and already receiving or
potentially needing insulin for blood glucose control were
screened for eligibility (Fig. 1). Exclusion criteria were: not
critically ill (monitoring only, not requiring vital organ
support), moribund on admission, younger than 18 years
of age, enrolled in another intervention trial, no arterial
line, pregnant or breast feeding, diabetic ketoacidosis or
hyperosmolar state on admission, previously included in
the LOGIC-2 trial, or declined participation.
Randomization
Consecutive patients were randomly allocated into either
the nurse-directed (Nurse-C) or the LOGIC-Insulin-
guided (LOGIC-C) group by a central computerized
system on a 1:1 ratio with permuted blocks of 10 per
stratum. Block size was unknown to all collaborators.
Randomization was stratified according to type of ad-
mission (post-cardiac surgery or other) and study center.
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Randomization of cardiac surgery patients was stopped
after reaching 60% of the total study population across
all centers. Outcome assessors, but not clinical staff,
were blinded to treatment allocation.
Intervention
Patients received blood glucose control according to the
assigned group: Nurse-C or LOGIC-C. An intravenous in-
fusion of insulin was started on admission in both groups
to aim for glycemia in the target range, which in the
Leuven and Hasselt ICUs was glycemia 80–110 mg/dL,
and in the Amsterdam ICU was glycemia 90–145 mg/dL.
Blood glucose targets were identical for both diabetic and
non-diabetic patients. In all centers and in both
randomization groups insulin treatment was initiated
when glycemia exceeded the upper limit of the target
range.
BGC was discontinued in both groups when the
patients started oral intake of carbohydrates, when the
arterial and/or central line was removed, when the
patient was discharged to the general ward or to an
external ICU, when palliative care was initiated, or when
recurrent severe hypoglycemic episodes (glycemia
<40 mg/dL) or refractory hyperglycemia (>180 mg/dL
and insulin at the aforementioned maximum rate) were
observed. Blood glucose concentrations were measured
in undiluted arterial blood by an on-site blood gas
analyzer, which differed between study sites. Insulin at a
concentration of 50 IU in 50 mL of saline was infused
through a central venous catheter, preferably via a
dedicated lumen, using a syringe pump.
BGC in the Nurse-C group was based on the existing
local documented guidelines. All bedside nurses had
undergone training in blood glucose management during
their schooling as an ICU nurse in the different units.
No specific training in BGC was given to nurses
performing BGC in the Nurse-C group for the purpose
of this study. Hence there was a range of experience in
dealing with insulin in the context of BGC. The bedside
nurse decided on the timing of blood glucose sampling
and the adjustment of the insulin infusion rate according
to the best clinical practice.
The LOGIC-insulin algorithm guided BGC in the
LOGIC-C group. The LOGIC-Insulin software is an
open loop system that advises the nurse on the dose of
insulin administration, or on dextrose in the case of
hypoglycemia, and on the timing of the subsequent
blood glucose measurement. It also entails visual warn-
ings about sampling time, hypoglycemia and potential
user entry errors, such as nutrition. All LOGIC-Insulin
advices have to be confirmed by the bedside nurse and,
if appropriate, can be overruled. The heart of the
LOGIC-Insulin algorithm itself is a robust, biphasic, and
adaptive patient model. The first phase consists of two
main parameters: patient profile on the one hand and
admission variables, such as diabetes mellitus and the
Fig. 1 Recruitment of patients into the study. All patients admitted to the ICU in the three participating centers from 24 February 2014 until 17 December
2014, in whom blood glucose control needed to be initiated, were screened for eligibility. This resulted in 1550 patients who were randomized and
analyzed (923 patients after cardiac surgery and 627 patients for other reasons as predefined). All patients were included in the primary analysis. LOGIC-C
patients randomized to algorithm-guided blood glucose control, Nurse-C patients randomized to blood glucose control by trained nurses
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severity of illness, on the other hand. The second phase
comprises five variables: patient profile, blood glucose,
insulin dose sequence, the administration of steroids,
and nutrition.
Further, the algorithm includes both feedback and
predictive mechanisms allowing estimation of the effect
of future disturbance factors [25, 26]. The combination
of both feedback and predictive mechanisms distin-
guishes the LOGIC-Insulin algorithm from other
computerized protocols such as EndoTool since these
are mainly based on feedback mechanisms [23]. The
LOGIC-Insulin algorithm can be compared to STAR, a
computer algorithm that is also based on feedback and
predictive mechanisms and which has already been
evaluated in two different ICUs [24].
The LOGIC-Insulin algorithm was designed and con-
figured in the pre-study phase to deal with varying blood
glucose target ranges. Since there was a 1:2 to 1:3 nurse-
patient ratio in the participating hospitals, nurses may
have had to treat patients in the two different groups:
Nurse-C and LOGIC-C.
Outcomes and measures
The primary outcome measure of the LOGIC-2 trial was
quality of blood glucose control, assessed by the
glycemic penalty index (GPI) per patient, during the
intervention period, censored at 14 days. This index
gives a penalty to all glucose values falling in the
hypoglycemic and hyperglycemic zones with a higher
penalty value for larger deviations from normoglycemia
[27]. The average of all penalties is summarized as the
GPI, ranging from 0 to 100.
The other outcome measures of BGC were in line with
the recent consensus recommendations on reporting of
glycemia in critically ill patients [28]. The most import-
ant safety outcome measure was the incidence of severe
hypoglycemia (<40 mg/dL). The incidence per patient
and the incidence as a proportion of all blood glucose
measurements were reported. The incidence of extended
hyperglycemia, defined as three consecutive blood
glucose measures >180 mg/dL, was added by the DSMB
as a safety outcome measure.
Other secondary endpoints were the incidence of mild
hypoglycemia (<70 mg/dL), mean arterial blood glucose
concentration, hyperglycemic index (area under the
curve in the hyperglycemic zone), time-in-target range,
time-to-reach-target range, maximal blood glucose
difference (marker of blood glucose variability) and the
interval between blood glucose measurements (marker
of workload), all reported as per-patient metrics with the
exception of the incidence of mild hypoglycemia, which
is presented both as the incidence per patient and the
incidence per proportion of measurements. In the inter-
vention group protocol compliance (patients in whom
the LOGIC-insulin software was not followed for a
period of at least 8 h) and overrules (recommendations
that were not followed by the bedside nurse) of the soft-
ware were assessed. A distinction was made between
minor (absolute insulin dose difference of > 0.1 IU/h and
<1 IU/h) and major (≥1 IU/h) overrules.
Clinical safety endpoints were the incidence of new
infections in the ICU (as scored by a blinded infectious
disease specialist), ventilator days per patient (censored at
14 days), length of stay in the ICU and in the hospital,
mortality in ICU and in hospital, and the landmark 90-day
mortality. Quality of life was assessed using the EuroQol
5D-3 L questionnaire at ICU admission, ICU discharge
and 90 days post-randomization. Sepsis was diagnosed,
using the American College of Chest Physicians-Society of
Critical Care Medicine criteria [29].
Statistical analyses
The study was conceived as a superiority trial for im-
proving the quality of blood glucose control, measured
by GPI and the time-in-target range, and it was also
powered to detect differences in the incidence of mild
hypoglycemia (<70 mg/dL) as a safety outcome variable.
The sample size calculations were preregistered at the
Belgian Federal Agency for Medicines and Health Prod-
ucts. Better performance in BGC in the Nurse-C group
was anticipated, as nurses would feel they were to be
watched (Hawthorne effect). On the basis of a 5% confi-
dence level (α error) and a 90% statistical power (β error
10%) the study required 458 patients in each arm to
detect a decrease in GPI from mean 21 to 18 (sigma 14)
in a two-sided test. An increase in the time-in-target
range from 45% to 50% with a sigma 29% would require
707 patients per arm. For a decrease in mild
hypoglycemia from 27% to 20% (ARR 7%) the study re-
quired 769 patients in each arm. To take into account
withdrawals, the study was set up for 1550 patients (775
patients in each group).
A subgroup analysis per study center and blood glu-
cose target was preplanned. The following subgroup
analyses for specific patient populations were also
planned: cardiac surgery, medical, sepsis on admission,
infection on admission, and known diabetes mellitus.
Variables were summarized as frequencies and per-
centages, mean and standard deviation (SD) or median
and interquartile range (IQR), as appropriate. Confi-
dence intervals were computed based on the bootstrap
percentile method for the primary and secondary
endpoints [30].
All analyses were done on an intention-to-treat
basis. Data were compared using the chi-square (χ2)
(Fisher exact) test, Student t test, or nonparametric
(Wilcoxon rank sum) test as appropriate. For all
endpoints, differences were considered statistically
Mesotten et al. Critical Care  (2017) 21:212 Page 4 of 10
significant whenever the two-sided P value was <0.05,
without correction for multiple testing. For the statis-
tical analyses, JMP Pro 11 (SAS Institute, Cary, NC,
USA) and Matlab (MathWorks, Natick, MA, USA)
were used.
Results
Study participants
A total of 3302 patients were screened for eligibility, of
whom 1550 (47%) gave consent and were randomized to
either Nurse-C or LOGIC-C (Fig. 1). None of the pa-
tients was lost to follow up. The baseline characteristics
of the treatment groups were similar (Table 1). The
percentage of admissions after cardiac surgery was 59%
and 60% in the Nurse-C and the LOGIC-C group,
respectively. On admission, 21.6% of patients had known
diabetes mellitus and 28% an infection.
Blood glucose control
The GPI, the primary outcome measure, was 6.3 points
lower in the LOGIC-C group than in the Nurse-C group
(P < 0.001) (Table 2). Time-in-target range was increased
from 47.1% in the Nurse-C group to 67.0% in LOGIC-C
group (P < 0.001). Mean blood glucose levels and the
hyperglycemic index were also lower in the LOGIC-C
group (all P < 0.001). Moreover, blood glucose variability
was decreased in the LOGIC-C group (P < 0.001). The
proportion of patients experiencing at least one episode
of hypoglycemia did not differ between treatment groups
(all P > 0.07). However, the proportion of blood glucose
readings <70 mg/dL and <60 mg/dL was smaller in the
LOGIC-C group (both P = 0.02). None of the subjects in
either randomized group experienced recurrent severe
hypoglycemic episodes or refractory hyperglycemia that
warranted withdrawal from the study. Workload was
higher in the LOGIC-C group, as reflected in a 23%
shorter sampling interval (P < 0.001).
Predefined subgroups
The effect of the LOGIC-Insulin algorithm on BGC was
more pronounced in Hasselt and Amsterdam (Fig. 2).
While the GPI was 3.6 points lower in the Leuven
LOGIC-C group, the difference was 10.1 in Hasselt and
15.1 in Amsterdam (Additional file 1: Tables S1-S3). Fur-
thermore, LOGIC-Insulin-guided BGC resulted in mean
blood glucose levels in the target range for Hasselt
(110 mg/dL) and Amsterdam (134 mg/dL), whereas
those in the Nurse-C group were above the target range,
at 123 mg/dL and 150 mg/dL, respectively. This was in
contrast to Leuven, where the mean blood glucose level
was in the target range in both the Logic-C (106 mg/dL)
and the Nurse-C (109 mg/dL) groups. While the inci-
dence of mild hypoglycemia decreased in the Leuven
LOGIC-C group, it increased in the Hasselt LOGIC-C
group, compared with their respective Nurse-C groups.
In all three centers, the sampling interval was shorter in
the LOGIC-C, compared with the Nurse-C group.
The quality of BGC was improved by the algorithm
in the predefined subgroups of cardiac surgery
(Additional file 1: Table S4), medical admission
(Additional file 1: Table S6), sepsis on admission
(Additional file 1: Table S8), infection on admission
(Additional file 1: Table S10) and known diabetes
mellitus (Additional file 1: Table S12).
Factors interfering with blood glucose control and
compliance with the LOGIC-Insulin software during the
study period
Patients in the LOGIC-C group received a larger daily in-
sulin dose (median 32 IU/day IQR 18–48 versus median
27 IU/day IQR 14–43 in the Nurse-C group) (P < 0.001).
The median daily amount of carbohydrates was 42 g (IQR
Table 1 Baseline characteristics
Nurse-C LOGIC-C
Total 773 777
Age, mean (SD), years 66 (15) 66 (14)
Male, n (%) 478 (62) 495 (64)
BMI, mean (SD), kg/m2 26.4 (5.2) 26.3 (4.9)
Diabetes, n (%) 167 (21.6) 168 (21.6)
Chronic dialysis, n (%) 17 (2) 11 (1)
APACHE-II score, mean (SD) 20 (9) 21 (9)
Admission type
Cardiac surgery, n (%) 458 (59) 465 (60)
Other surgery, n (%) 164 (21) 130 (17)
Medical, n (%) 131 (17) 164 (21)
Transplantation, n (%) 20 (3) 18 (2)
Adm mechanical ventilation,
n (%)
661 (86) 657 (85)
Adm insulin infusion, n (%) 171 (21) 164 (22)
Adm blood glucose level
(mg/dL), median (IQR)
127 (108–153) 128 (106–153)
Adm hypoglycemia
(<40 mg/dL), n (%)
1 (0.1) 1 (0.1)
Adm blood lactate level
(mmol/L), median (IQR)
1.3 (1.0–1.9) 1.3 (1.0–2.0)
Adm infection, n (%) 219 (28) 217 (28)
Adm sepsis, n (%) 102 (13) 129 (17)
Adm EQ-5D value index (%),
median (IQR)
0.72 (0.35–1) 0.71 (0.33–0.90)
Adm EQ-5D VAS score (%),
median (IQR)
0.65 (0.50–0.80) 0.65 (0.42–0.80)
Data are mean (SD), median (IQR) or n (%) LOGIC-C patients randomized to
algorithm-guided blood glucose control, Nurse-C patients randomized to blood
glucose control by trained nurses, APACHE-II Acute Physiology and Chronic
Health Evaluation-II, BMI body mass index, Adm admission, EQ-5D Euroqol-5D,
VAS visual analog scale
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31–68) in the LOGIC-C and 42 g (IQR 30–70) in the
Nurse-C group (P = 0.88). The number of LOGIC-C
patients who received steroids (24.1%) was comparable to
the Nurse-C group (21.7%) (P = 0.28). Also the proportion
of patients on mixed-bag parenteral nutrition did not dif-
fer between the LOGIC-C (7.3%) and the Nurse-C (10.0%)
groups (P = 0.07). The number of days patients received
inotropics/vasopressors (2 days, IQR 1–3 versus 2 days,
IQR 1–3) and antibiotics (1 day, IQR 1–3 versus 2 days,
IQR 1–3) did not differ between treatment groups (both
P > 0.39).
In 80/777 patients (10.3%) in the LOGIC-C group, the
software had not been used for more than 8 h. In total
240 minor and 147 major overrules occurred in the
LOGIC-C group, representing 1.15% and 0.70% of blood
glucose measurements, respectively. Of the major
overrules, 14 (9.5%) were justified, and of these only 2
overrules were made to avoid hypoglycemia, represent-
ing 2/777 LOGIC-C patients (0.3%). In Amsterdam the
proportion of overrules (minor 19 (1.71%), major 20
(1.80%) for insulin dosing advice given in 1114 in-
stances) was higher than in Leuven (minor 155 (1.30%),
major 89 (0.75%) for insulin dosing advice given in
11926 instances) and Hasselt (minor 66 (0.84%), major
38 (0.48%) for insulin dosing advice given in 7892
instances) (P < 0.001).
Clinical safety outcomes
The clinical outcomes did not differ between the treat-
ment groups (Table 3 and Additional file 1: Table S16).
However, in patients with sepsis on admission the inci-
dence of new infections was lower in the LOGIC-C
(20.16%) than in the Nurse-C group (33.33%) (P = 0.034).
In patients with an infection on admission, the incidence
of new infections was 23.04% in the LOGIC-C, compared
with 31.96% in the Nurse-C group (P = 0.042). For all
other predefined subgroups (cardiac surgery, medical
admission, and diabetes mellitus) the incidence of new
infections was comparable between treatment groups.
Discussion
Using the LOGIC-Insulin algorithm improved the
quality of BGC reflected by a reduction in the GPI, an
increase in time-in-target range and a reduction in blood
Table 2 Blood glucose control in the two randomized groups
Nurse-C LOGIC-C P value
95% CI 95% CI
Patients 773 777
Study period, median (IQR), days 2 (2–4) 2 (2–4)) 0.7
Efficacy
Glycemic penalty index (GPI), median (IQR) 17.1 (10.6–26.2) 16.3–18.1 10.8 (6.2–16.1) 10.0–11.5 <0.001
Blood glucose, mean (SD), mg/dL 119 (21) 118–121 111 (15) 110–112 <0.001
Minimum blood glucose, mg/dL 21 26
Maximum blood glucose, mg/dL 428 511
Hyperglycemic index, median (IQR), mg/dL 8.3 (3.4–16.3) 7.5–8.8 3.5 (1.4–7.0) 3.1–4.0 <0.001
Time-in-target range, median (IQR), percentage 47.1 (28.1–65.0) 45.7–49.3 67.0 (52.1–80.1) 65.4–68.6 <0.001
Time to reach target range, median (IQR), h 3.6 (0–9.3) 3.2–4.3 2.2 (0–5.1) 1.8–2.5 <0.001
Mean of maximum delta glycemia per day, median (IQR), mg/dL 36 (27–52) 35–38 34 (24–46) 32–36 <0.001
Safety
Hypoglycemia, proportion of patients
<70 mg/dL, n (%) 173 (22.4) 151–196 149 (19.2) 128 –171 0.1
<60 mg/dL, n (%) 78 (10.1) 62–95 58 (7.5) 44–73 0.07
<40 mg/dL, n (%) 9 (1.2) 4–15 7 (0.9) 2–13 0.6
Hypoglycemia, proportion of samples
<70 mg/dL, n (%) 346 (1.8) 311–382 342 (1.5) 306–379 0.02
<60 mg/dL, n (%) 123 (0.7) 102–145 105 (0.5) 85–125 0.02
<40 mg/dL, n (%) 9 (0.05) 4–15 9 (0.04) 4–15 0.9
Workload
Sampling interval, mean (SD), h 3.0 (0.8) 2.9–3.0 2.3 (0.5) 2.3–2.3 <0.001
Data are mean (SD), median (IQR) or n (%). LOGIC-C patients randomized to algorithm-guided blood glucose control, Nurse-C patients randomized to blood glucose
control by trained nurses
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glucose variability, without increasing the incidence of
hypoglycemia.
The beneficial effects of software-guided BGC were
independent of the chosen target blood glucose range
and of the center’s expertise in BGC. Morbidity and
mortality did not differ between patients in whom BGC
was done either by expert nurses or aided by the
LOGIC-Insulin algorithm in the context of similar blood
glucose target ranges.
These data confirm the findings from our single center
trial, in which LOGIC-Insulin improved tight BGC and
lowered the incidence of mild hypoglycemia [25]. How-
ever, the treatment effect in the pragmatic multicenter
LOGIC-2 trial was twofold that in the LOGIC-1 trial
and that for which it was statistically powered. This was
explained by more pronounced benefits of algorithm-
guided BGC in centers with looser BGC. The perform-
ance of the Leuven nurses in BGC, incorporated in the
LOGIC-Insulin algorithm, may also have blunted the
effect in Leuven. Similar blood glucose profiles in the
software groups in Leuven and Hasselt, using the same
target range, demonstrate that the LOGIC-Insulin soft-
ware can be generalized outside the context of centers
with extensive BGC experience. The fact that more than
98% of all insulin dosing advice provided by the LOGIC-
Insulin algorithm were followed by the nurses in all
centers in the algorithm-guided BGC group indicates
high protocol compliance and indicates that the results
are protocol-induced and not a representation of the
nurses’ BGC performance in the intervention group.
This further underpins the generalizability of the study
findings and the potential for implementation of the
LOGIC-Insulin software, independent of the chosen
blood glucose target range. This is important as the
interaction between the BGC algorithm and patient glu-
cose dynamics may be influenced by the performance of
Fig. 2 Blood glucose control and numbers of patients in the two randomized groups during the first 3 days in the ICU, per study center. Upper panels
overall mean blood glucose levels (mg/dL) for both the algorithm-guided (dashed line) and the nurse-directed (solid line) blood glucose control group
per center during the first 72 h in the ICU, which is the median ICU stay. The average blood glucose is computed over all glucose samples (per center)
belonging to the previous 4-h time slot. The glycemic target range was 80–110 mg/dL for Leuven and Hasselt, unlike Amsterdam where the glycemic
target range was 90–145 mg/dL. Lower panels the number of patients for the Nurse-C group (Nurse) (black bars) and LOGIC-C group (LOGIC) (gray bars)
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the bedsides nurses, who are the ultimate “controllers”
in open-loop BGC software.
The larger treatment effect in the broader target range
of 90–145 mg/dL (delta GPI 15.1) than in the narrow
target range of 80–110 mg/dL (delta GPI 5.7) was there-
fore not anticipated. One might have expected that BGC
is easier for nurses when the target is broader. This indi-
cates that nurses, in the context of a broader target
range, tend to be more lenient towards the upper target
limit. The higher incidence of extended hyperglycemia
above 180 mg/dL reflects this, in spite of the consensus
in all guidelines on BGC in the ICU that excessive
hyperglycemia should be avoided. Nevertheless, the
higher incidence of overrules in Amsterdam, possible
practical differences in the insulin administration, and
greater statistical uncertainty due to the smaller patient
numbers may have contributed as well. Most likely,
BGC will be even looser outside study settings. In con-
trast, use of the narrower target range results in greater
incidence of mild hypoglycemia. Algorithm-guided BGC
did not increase the incidence of potentially harmful,
severe hypoglycemia, which should always be strictly
avoided. A recent randomized controlled trial used com-
puterized insulin-dosing algorithms in the intensive
BGC group, but did not show a clinical difference with
more conservative, nurse-directed BGC [31].
Algorithm-guided BGC increased the workload, similar
to other algorithms [32]. Ten instead of eight blood glucose
measurements per day were needed to improve BGC in
one patient by software use. The workload of blood glucose
measurements may be offset by lowering of the cognitive
burden for the nurses in deciding on the right insulin dose
[33]. Hence, this slight increase in workload may be inevit-
able in obtaining safe and effective blood glucose control,
especially in the initial phase, aiming for a short time to
reach the chosen target range combined with a high time-
in-target range, low glucose variability, and avoidance of
hypoglycemia, and this in a setting with rapid changes in
patients insulin sensitivity and in the presence of external
confounding factors such as use of steroids and parenteral
nutrition. There is now a consensus that a minimal meas-
urement frequency is needed to provide safe glycemic con-
trol without adverse effects on the outcome [28]. Whether
the increased workload resulted in more attention paid to
the patient (collateral benefit) or less attention to the pa-
tient (added risk) cannot be delineated from this study.
The improvement in BGC provided by the software was
comparable in all patient populations, such as cardiac sur-
gery, pre-existing diabetes, sepsis, and medical admissions.
However, the clinical effects of improved BGC should be
the ultimate determinants to evaluate medical interven-
tions. Although the LOGIC-2 trial was not set up to test
differences in clinical outcomes, it was monitored. As ex-
pected, no clinical differences were seen in the overall pa-
tient population. Patients with diabetes mellitus did not
benefit more from algorithm-guided BGC, as was seen in
a recent trial of BGC in patients after coronary artery by-
pass graft surgery [34]. However, the level of pre-admis-
sion control of the diabetes mellitus may be the most
important factor in determining whether patients benefit
from tight BGC.
In patients with infectious problems on admission, im-
proved BGC resulted in lowering of the incidence of
new infections. This may be explained by the fact that
patients with infectious problems on admission are more
severely ill, have greater risk of more severe hypergly-
cemia, which is more difficult to control, and have
greater risk of new infections.
The LOGIC-2 trial has its limitations though. Blood glu-
cose dynamics in the ICU are determined by patient
Table 3 Clinical safety outcome measures
Nurse-C LOGIC-C P value
Patients 773 777
Length of ICU stay, median (IQR), days 3 (2–6) 3 (2–6) 0.39
Length of hospital stay, median (IQR), days 12 (8–23) 12 (8–23) 0.18
Mortality in the ICU, n (%) 41 (5.30) 47 (6.05) 0.61
Mortality in the hospital, n (%) 84 (10.81) 72 (9.31) 0.35
Mortality at 90 days, n (%) 89 (11.71) 91 (11.51) 0.93
Incidence of new infections in the ICU, n (%) 117 (15.14) 104 (13.38) 0.35
Ventilator days, median (IQR), days 1 (1–2) 1 (1–3) 0.85
EQ-5D index value at ICU discharge, median (IQR) 0.28 (0.13–0.58) 0.29 (0.13–0.58) 0.59
EQ-5D index value at 90 days, median (IQR) 0.73 (0.56–1) 0.73 (0.56–1) 0.58
EQ-5D VAS score at ICU discharge, median (IQR) 0.60 (0.50–0.70) 0.60 (0.50–0.70) 0.42
EQ-5D VAS score at 90 days, median (IQR) 0.70 (0.60–0.80) 0.70 (0.60–0.80) 0.97
Data are mean (SD), median (IQR) or n (%). LOGIC-C patients randomized to algorithm-guided blood glucose control, Nurse-C patients randomized to blood glucose
control by trained nurses, EQ-5D Euroqol-5D, VAS visual analog scale
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characteristics, by the BGC protocol, and by the experience
of the bedside nurses in executing the BGC. Therefore, the
differences in the quality of BGC in the Nurse-C group be-
tween the centers are most likely multifactorial. The variabil-
ity in the “baseline” quality of BGC may have affected the
performance using the LOGIC-Insulin software. It can also
not be excluded that nursing practice in performing BGC
changed over time during the study, under the influence of
the algorithm. However, participating in a study on BGC
had most likely improved the performance of BGC by the
nurses over time due to a training effect. The LOGIC-
Insulin software was now only tested when using glucose
readings from arterial blood measured in accurate blood gas
analyzers. To gain further applicability the software should
be able to cope with blood glucose measurements from
point-of-care, handheld blood glucose meters. Other com-
puterized protocols however, have already used these point-
of-care glucometers showing a safe and efficient level of
blood glucose control [23, 24]. Efficiency or cost-
effectiveness of the LOGIC-Insulin software is still un-
proven, despite that the present pragmatic multicenter RCT
showed that the software works in real-life circumstances.
Conclusions
In a randomized controlled trial of a mixed critically ill
patient population, the use of the LOGIC-Insulin blood
glucose control algorithm, compared with blood glucose
control by expert nurses, improved the quality of blood
glucose control without increasing hypoglycemia. This is
demonstrated by an important improvement in all do-
mains of glycemic control: a decrease in GPI, an increase
in the time-in-target range, and a decrease in glucose
variability. Moreover, the LOGIC-Insulin algorithm was
shown to be efficient and safe when used in three differ-
ent ICUs with local variations in clinical practice, with
different blood glucose target ranges, and with different
levels of experience in blood glucose control. The slight
increase in workload generated by the LOGIC-insulin al-
gorithm should be considered an inevitable trade-off
when providing safe and efficient blood glucose control.
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